1. Home
  2. TG vs SKYE Comparison

TG vs SKYE Comparison

Compare TG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

N/A

Current Price

$7.16

Market Cap

262.4M

Sector

Industrials

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$2.04

Market Cap

20.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TG
SKYE
Founded
1988
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
262.4M
20.0M
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
TG
SKYE
Price
$7.16
$2.04
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
129.0K
554.1K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
151.06
N/A
EPS
0.34
N/A
Revenue
$800,821,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.74
N/A
Revenue Growth
8.29
N/A
52 Week Low
$6.25
$0.26
52 Week High
$10.53
$4.99

Technical Indicators

Market Signals
Indicator
TG
SKYE
Relative Strength Index (RSI) 37.00 69.22
Support Level $7.14 $0.58
Resistance Level $8.12 $2.32
Average True Range (ATR) 0.20 0.19
MACD -0.04 0.05
Stochastic Oscillator 0.61 87.61

Price Performance

Historical Comparison
TG
SKYE

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: